ViiV opens up brand-new HIV med Tivicay for cheap copies in poor countries

HIV drug specialist ViiV Healthcare has tossed a brand-new product into the Medicines Patent Pool. ViiV--a joint venture of GlaxoSmithKline ($GSK), Pfizer ($PFE) and Shionogi--inked a deal with MPP to speed access to cheap copies of Tivicay (dolutegravir) in developing countries. Among the pricier HIV treatments, Tivicay was FDA-approved last year, and analysts figure it could hit $5 billion in sales. Report

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

A lawsuit says J&J helped doctors set up high-volume "infusion suites" and offered other services as kickbacks to amp up Remicade and Simponi…

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.